$BXLT News

Last published 6mo ago

6mo agoBAX BMRN BXLT4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of DirectorsBusiness WireFinancing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D
1y agoBAX BMRN EMBC HSIC+2PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee ChairBusiness WireFormer Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a
1y agoBAX BMRN EMBC HSIC+1Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee ChairBusiness WireFormer Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company
10y agoBXLT SHPGCORRECTING and REPLACING Baxalta Shareholders Vote to Approve CombinationBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--First paragraph, second sentence of release should read: Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 76.9 percent of shares outstanding cast in favor of the proposal, which represents approximately 98.9 percent of the votes cast at the meeting (instead of B ...
10y agoBXLTOncoResponse Secures Investment from BaxaltaBusiness WireHOUSTON & BANNOCKBURN, Ill.--(BUSINESS WIRE)--OncoResponse, an immuno-oncology antibody discovery company, today announced an investment from Baxalta Incorporated (NYSE: BXLT). In October 2015, OncoResponse closed a Series A financing co-led by ARCH Venture Partners, Canaan Partners and MD Anderson, with William Marsh Rice University and Alexandria Real Estate Equities also participating. The inve ...
10y agoBXLTBaxalta Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)Business WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported positive results from a Phase 1 open-label, dose escalation study assessing the safety and pharmacokinetic (PK) profile of BAX 930, an investigational recombinant ADAMTS1 ...
10y agoBXLTThunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.Business WireBANNOCKBURN, Ill. & SAN FRANCISCO & TOKYO--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), Velocity Pharmaceutical Development, LLC (VPD) and Astellas Pharma Inc. (TSE:4503) today announced that Thunderbolt, Inc., a company established by Vitesse Biologics, acquired all rights to the Astellas BAFF/APRIL dual antagonist program through an asset purchase agreement. The BAFF/APRIL dual antagonist ...
10y agoBAX BXLTBaxter Announces Final Results of Baxalta Exchange OfferBusiness WireDEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) (''Baxter'') announced today the final results of Baxter’s previously announced offer to exchange up to 13,360,527 shares of common stock of Baxalta Incorporated (NYSE: BXLT) (''Baxalta'') owned by Baxter for shares of Baxter common stock. The exchange offer expired at 11:59 p.m., New York City time, on May 18, 2016. Under the ...
10y agoBXLT SHPGBaxalta Announces Preliminary Merger Consideration Election ResultsBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) today announced the preliminary results of the elections made by its stockholders as to the form of stock consideration to be received in Baxalta’s merger with Shire plc (LSE: SHP, NASDAQ: SHPG).
10y agoBAX BXLTBaxter Announces Preliminary Results of Baxalta Exchange OfferBusiness WireDEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) (“Baxter”) announced today the preliminary results of Baxter’s previously announced offer to exchange up to 13,360,527 shares of common stock of Baxalta Incorporated (NYSE: BXLT) (“Baxalta”) that are currently owned by Baxter for shares of Baxter common stock. The exchange offer expired at 11:59 p.m., New York City time, on Ma ...
10y agoBAX BXLTBaxter Announces Final Exchange Ratio of 1.1591 for Baxalta Exchange OfferBusiness WireDEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) (“Baxter”) announced today the final exchange ratio in connection with its previously announced offer to exchange up to 13,360,527 shares of common stock of Baxalta Incorporated (NYSE: BXLT) (“Baxalta”) that are currently owned by Baxter for shares of Baxter common stock.
10y agoBXLT SHPGBaxalta Declares Quarterly DividendBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--The Board of Directors of Baxalta Incorporated (NYSE: BXLT) today declared a quarterly cash dividend of $0.07 per share of common stock. The quarterly dividend will be paid on July 1, 2016, to stockholders of record as of the close of trading on the New York Stock Exchange on June 10, 2016.
10y agoBAX BXLTBaxter Increases the Size of Its Previously Announced Offer to Exchange Shares of Baxter for Shares of BaxaltaBusiness WireDEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) (''Baxter'') announced today that it has increased the size of its offer to exchange shares of Baxalta Incorporated (NYSE: BXLT) (''Baxalta'') common stock that are currently owned by Baxter for shares of Baxter common stock that are validly tendered and not validly withdrawn in its previously announced exchange offer. The num ...
10y agoKMDA BXLTKamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and BaxaltaBusiness WireNESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces receipt of two milestone payments as a result of achieving certain regulatory and sales milestones under the strategic agreements with Chiesi Farmaceutici S.p.A. and Baxalta Incorporated (NYSE: BXLT).
10y agoBXLTBaxalta Receives Positive Opinion from Europe’s CHMP for HYQVIA to Treat Pediatric PatientsBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--NOT FOR U.S. AUDIENCES
10y agoBXLT BAX SHPGBaxalta Exceeds Guidance and Delivers Strong Sales and Earnings for First Quarter 2016Business WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported strong first quarter 2016 financial results.
10y agoBAX BXLTBaxter Initiates Offer to Exchange Shares of Baxter for Shares of BaxaltaBusiness WireDEERFIELD, Ill. & BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) (“Baxter”) and Baxalta Incorporated (NYSE: BXLT) (“Baxalta”) announced today that Baxter has commenced an offer to exchange up to 12,800,000 shares of Baxalta common stock that are currently owned by Baxter, which represents approximately 1.9% of the outstanding common stock of Baxalta, for shares of Baxter ...
10y agoBXLTBaxalta Supports Research to Raise Awareness of Treatment Burden on Patients during the Sixth Annual World Primary Immunodeficiency WeekBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today celebrates progress and reaffirms its commitment to supporting the global primary immunodeficiency (PI) community during the sixth annual World PI Week, April 22-29, 2016. As part ...
10y agoBXLT SHPGBaxalta Announces Date for Special Meeting of Stockholders to Vote on Combination With ShireBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) announced today that the special meeting of stockholders to adopt the merger agreement with Shire plc (LSE:SHP, NASDAQ:SHPG) will be held on May 27, 2016, at 7:00 a.m. Central Time, for shareholders of record as of the close of business on April 11, 2016. The special meeting will be held at Baxalta’s corporate headquarters, locat ...
10y agoKMDA BXLTKamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant RejectionBusiness WireNESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces in the initiation of a Phase 2 clinical trial with its proprietary Alpha-1 Antitrypsin (AAT) for the prevention of lung transplant rejection. The study is being conducted in collaboration with Baxalta Incorporated (NYSE: BXLT), which has ...
10y agoBXLT NKTRBaxalta Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in JapanBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinan ...
10y agoBXLTBaxalta Announces Pricing of Secondary Offering of Common StockBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT) announced today the pricing of its previously announced secondary public offering of 63,823,582 shares of its common stock at a price to the public of $37.75 per share. Baxalta is not selling any shares and will not receive any proceeds from the sale of the shares in the offering or the debt-for-equity exchange (as described bel ...
10y agoBXLTBaxalta Announces Secondary Offering of Common StockBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT) announced today the commencement of an underwritten public offering of approximately $2.34 billion of its common stock previously issued to and currently owned by Baxter International Inc. (“Baxter”), Baxalta’s former parent company. Baxalta is not selling any shares and will not receive any proceeds from the sale of the shares ...
10y agoBXLT NKTRBaxalta Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia ABusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has dosed the first patient in its Phase 1, first-in-human clinical trial of BAX 826, a recombinant Factor VIII (rFVIII) treatment for hemophilia A that uses prop ...
10y agoBXLTBaxalta to Showcase Innovation Leadership in Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual MeetingBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, will present data highlighting its commitment to innovation in primary immunodeficiencies (PI) at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, March ...
10y agoBXLT NKTRBaxalta Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A PatientsBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ADYNOVI, an extended circulating half-life recomb ...
10y agoBXLT NKTRBaxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical SettingsBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of ADYNOVATE [Antihe ...
10y agoBXLTBaxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-OncologyBusiness WireBANNOCKBURN, Ill. & DURHAM, N.C.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Precision BioSciences, the genome editing company, today announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T ce ...
10y agoBXLTBaxalta Declares Quarterly DividendBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--The Board of Directors of Baxalta Incorporated (NYSE: BXLT) today declared a quarterly cash dividend of $0.07 per share of common stock. The quarterly dividend will be paid on April 1, 2016, to stockholders of record as of the close of business on March 10, 2016.
10y agoBXLT BAX SHPGBaxalta Posts Strong Fourth Quarter 2015 Sales and Earnings; Positive Momentum Continues with Achievement of Key MilestonesBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported strong fourth quarter 2015 financial results.
10y agoBXLTBaxalta to Report Fourth Quarter and Full-Year 2015 Results on February 16, 2016Business WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) will announce its fourth quarter and full-year 2015 financial results on Tuesday, Feb. 16, 2016, before the market opens.
10y agoBXLTBaxalta Announces Pricing of Secondary Offering of Common StockBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT) announced today the pricing of its previously announced secondary public offering of 37,573,040 shares of its common stock at a price to the public of $39.50 per share. Baxalta is not selling any shares and will not receive any proceeds from the sale of the shares in the offering or the debt-for-equity exchange (as described bel ...
10y agoBXLTBaxalta Announces Secondary Offering of Common Stock Owned by Baxter InternationalBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT) announced today the commencement of an underwritten public offering of approximately $1.45 billion of its common stock previously issued to and currently owned by Baxter International Inc., Baxalta’s former parent company. Baxalta is not selling any shares and will not receive any proceeds from the sale of the shares in the offe ...
10y agoBXLTBaxalta Granted EU Marketing Authorization for ONCASPAR (pegaspargase) as a Component of Combination Therapy in Acute Lymphoblastic Leukaemia (ALL)Business WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that the European Commission has granted Marketing Authorization for use of ONCASPAR as a combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patient ...
10y agoBXLTRobbins Arroyo LLP: Acquisition of Baxalta, Inc. (BXLT) by Shire PLC (SHP) May Not Be in Shareholders' Best InterestsBusiness WireSAN DIEGO & BANNOCKBURN, Ill.--(BUSINESS WIRE)--Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Baxalta Inc. (NYSE: BXLT) by Shire PLC (London: SHP). On January 11, 2016, the two companies announced the signing of a definitive merger agreement pursuant to which Shire PLC will acquire Baxalta. Under the terms of the agreement, Baxalta shareholders wi ...
10y agoBXLT SHPGBaxalta Cancels Presentation at 34th Annual J.P. Morgan Healthcare ConferenceBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta (NYSE:BXLT) announced today that it will not present at the 34th Annual J.P. Morgan Healthcare Conference, which was previously scheduled for Wednesday, Jan. 13, 2016, at 4:30 p.m. Central Time.
10y agoBXLTBaxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug SubmissionBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that Health Canada has granted Priority Review status for its New Drug Submission (NDS) for irinotecan liposome injection, also known as "nal-IRI". Baxalta is seeking ma ...
10y agoKMDA BXLTKamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host DiseaseBusiness WireNESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports further positive interim results from a Phase 1/2 clinical trial of its proprietary alpha-1 antitrypsin (AAT) to treat steroid-refractory Graft Versus Host Disease (GvHD) which is being conducted in collaboration with Baxalta US, Inc. (NYS ...
10y agoBXLTBaxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-OncologyBusiness WireBANNOCKBURN, Ill. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, today announced a broad strategic immuno-oncology colla ...
10y agoBXLT NKTRBaxalta’s ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of AgeBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rF ...
10y agoBXLTBaxalta to Present at 34th Annual J.P. Morgan Healthcare ConferenceBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) announced today that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016, at 4:30 p.m. Central Time.
10y agoBXLTBaxalta to Present at Goldman Sachs Healthcare CEOs Unscripted ConferenceBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Conference on Tuesday, Jan. 5, 2016, at 10:00 a.m. Central Time.
10y agoBXLTBaxalta Receives FDA Approval for VONVENDI, the First and Only Recombinant Treatment for Adults Affected by Von Willebrand DiseaseBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (Recombinant)]. VONVENDI is the first and only recombinant treatment for ad ...
10y agoBXLT NKTRBaxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology (ASH) Annual MeetingBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, is showcasing data on the clinical experience with newly-approved hemophilia A treatment ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] at the 57th American Society of Hemat ...
10y agoBXLTBaxalta Announces Opening of Global Innovation Center Dedicated to Pioneering Breakthroughs for Patients with Unmet NeedsBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced the official opening of its Global Innovation Center in Cambridge, Massachusetts. The Center is located in Kendall Square at 650 East Kendall Street and will act as the innova ...
10y agoBXLTBaxalta Receives CHMP Positive Opinion for Sanquin to Begin Production, Enhancing Global Supply of Plasma-Based TherapiesBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, licensing European production of HYQVIA ...
10y agoBXLTBaxalta to Showcase Innovation Leadership in Hematology and Oncology During 57th American Society of Hematology (ASH) Annual MeetingBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, will present data highlighting its commitment to innovation in blood disorders and hematologic oncology at the 57th American Society of Hematology (ASH) Annual Meeting, beginning today ...
10y agoBXLT NKTRBaxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients With Hemophilia A With a Simple, Twice-Weekly Dosing ScheduleBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved medical conditions, today announced the launch and first shipments of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant factor VIII (rFVIII) ...
10y agoBXLTBaxalta Receives Positive CHMP Opinion for Use of ONCASPAR (pegaspargase) in European Union as a Component of Combination Therapy in Acute Lymphoblastic Leukaemia (ALL)Business WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ...
10y agoBXLTBaxalta to Initiate a First-in-Human Clinical Trial of BAX 826, an Investigational, Extended Half-Life FVIII Treatment Targeting Weekly Dosing for Hemophilia ABusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced the submission of a Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a first-in-human clinical trial to ...